SL
VRTX icon

Sentinus LLC’s Vertex Pharmaceuticals VRTX Stock Holding History

Sentinus LLC’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$397K Buy
799
+186
+30% +$82.4K 0.03% 395
2026
Q1 		$274K Buy
613
+152
+33% +$70.9K 0.02% 455
2025
Q4 		$209K Buy
+461
New +$199K 0.02% 515

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Sentinus LLC's VRTX Position: Q2 2026 in Review

Sentinus LLC increased its Vertex Pharmaceuticals (VRTX) stake by 30% in Q2 2026, buying an estimated $82.4K and bringing the position to 799 shares worth $397K. The position accounts for 0.03% of the portfolio, ranked #395.

Sentinus LLC first reported a position in VRTX in Q4 2025 and has held it in 3 quarters since. 1,761 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Sentinus LLC held 799 shares of Vertex Pharmaceuticals worth $397K as of Q2 2026.
  • Sentinus LLC bought 186 Vertex Pharmaceuticals shares in Q2 2026, an estimated $82.4K.
  • Vertex Pharmaceuticals made up 0.03% of Sentinus LLC's portfolio in Q2 2026, its #395 holding.
  • Sentinus LLC first reported a position in Vertex Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 1,761 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Sentinus LLC's 13F filing for Q2 2026, filed 11 Aug 2026.